Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
Author:
Publisher
Elsevier BV
Subject
Transplantation,Hematology
Reference124 articles.
1. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century;Pulte;Br J Haematol,2015
2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma;Attal;N Engl J Med,1996
3. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003
4. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myélome-Autogreffe;Fermand;J Clin Oncol,2005
5. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA;Bladé;Blood,2005
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation;Heliyon;2024-03
2. Safety and efficacy of a new high‐dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high‐risk myeloma: Matched‐pair comparisons with concurrent control cohorts;American Journal of Hematology;2023-12-15
3. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results;Nature Medicine;2023-01-23
4. Myeloid-derived suppressor cells in multiple myeloma patients at the immune recovery and after high-dose chemotherapy and hematopoietic stem cell transplantation;Siberian journal of oncology;2022-12-29
5. Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial;Bone Marrow Transplantation;2022-04-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3